Kerecis

Isafjordur, Iceland Founded: 2007 • Age: 19 yrs Minicorn Acquired By Coloplast
Fish-skin acellular dermal matrix technology is provided for wound treatments.

About Kerecis

Kerecis is a Healthcare company based in Isafjordur (Iceland) founded in 2007, and was acquired by Coloplast in July 2023. Fish-skin acellular dermal matrix technology is provided for wound treatments. Kerecis has raised $93.11 million across 14 funding rounds from investors including SVB, Coloplast and European Union. The company has 150 employees. Kerecis has completed 1 acquisition, including Phytoceuticals. Kerecis was last valued at $620 million in July 2022. Its website kerecis.com draws about 26 thousand monthly visits. Kerecis offers products and services including MariGen, SurgiClose, SurgiBind, GraftGuide, and Shield. Its focus areas include Life Sciences, Regenerative Medicine, Biomaterials and Scaffolds. Its legal entity is KERECIS, LLC.

Company details

Founded in 2007 in Isafjordur, Iceland, the company operates in the medical technology sector, focusing on acellular fish-skin grafts. Omega3 technology is utilized in products for chronic wound management, hernia repair, breast reconstruction, and abdominal wall reconstruction. Advantages over human and porcine alternatives include better economics, enhanced clinical outcomes, lower disease transmission risks, and no cultural usage barriers. The domain kerecis.com supports global operations.

  • Headquarters Isafjordur, Iceland
  • Employees 150
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Website kerecis.com
  • Social LinkedIn X Facebook Instagram
  • Acquired by Coloplast (Jul 2023)
  • Legal Name Kerecis, Llc
Key Metrics
  • Total Equity Funding
    $93.11M (USD)

    in 14 rounds

  • Latest Funding Round
    $30M (USD), Series D

    Jul 2022

  • Investors
    SVB

    & 7 more

  • Employee Count
    150
  • Investments & Acquisitions
  • Acquired by
    Coloplast

    (Jul 2023)

Products & Services of Kerecis

Kerecis offers a comprehensive portfolio of products and services, including MariGen, SurgiClose, SurgiBind, GraftGuide, and Shield.

MariGen
Wound Graft

Fish skin graft for treating chronic wounds and ulcers.

SurgiClose
Surgical Product

Combination graft for soft-tissue repair in trauma.

SurgiBind
Burn Treatment

Product for burn wound healing and regeneration.

GraftGuide
Medical Device

Guide for applying fish skin in surgical procedures.

Shield
Wound Protection

Fish skin product for private office wound care.

Kerecis VET
Veterinary Product

Solutions for animal wound treatment and healing.

Funding Insights of Kerecis

Kerecis has successfully raised a total of $93.11M across 14 strategic funding rounds. The most recent funding activity was a Series D round of $30 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $93.11M
  • Total Rounds 14
  • Last Round Series D — $30M
  • Investors Count 7

Latest 10 of 14 funding rounds of Kerecis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2022$30MDebt – Venture––
Jul 2022$30MSeries D$620MKIRKBI A/S
Jun 2022$40MSeries C–KIRKBI A/S
–
Aug 2020Debt – Conventional––
Aug 2020Series C––
–
Jul 2020$109,567Series C––
–
Nov 2019$1.05MGrant––
May 2019$16MSeries C––
–
May 2018$1.5MDebt – Conventional––
–
Jan 2018$3MSeries B––
–
Valuation history
DateValuationStage
Jul 2022$620M••••••••

Last known valuation $620M (Jul 2022). 8 investors in total: 8 institutional.

Investors in Kerecis

Kerecis has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, Coloplast and European Union.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
KIRKBI is engaged in building a better future for children.
kirkbi.comBillund, Denmark
A venture capital fund focused on supporting innovative startups in Iceland.
nyskopun.isReykjavík, Iceland
Banking services are provided to innovative companies, investors, and individuals.
1983svb.comSanta Clara, United States
A pension fund is operated for Icelandic state employees.
lsr.isReykjavík, Iceland
Provides pension funds, loans, and savings services for individuals and employers.
2004lifbru.isReykjavik, Iceland
emersoncollective.com
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
1958europa.euBrussels, Belgium
Medical devices for ostomy, urology, and wound care are manufactured.
1957coloplast.comHumlebaek, Denmark
Premium access

Investor details for Kerecis

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Kerecis

129 people are tracked at Kerecis (56 in leadership, 73 in team); the tracked headcount is 150.

NameRoleGroup
Baldur Tumi Baldursson
Co-founder & Medical DirectorLeadership
Christopher Harte
Chief Operating Officer, Global Markets & TechnologiesLeadership
G. Fertram Sigurjonsson
Founder, Chairman, President & CEOLeadership
Rob Cruickshank
Dermatology | Mohs DirectorLeadership
Tryggvi Gunnarsson
Director Of Regulatory AffairsLeadership
Skuli Magnusson
VP Regulatory, Quality And Clinical AffairsLeadership
Daniel Stack
Regenerative Burn, Trauma, & Surgical Director--scLeadership
Rob Tomko
Regenerative Burn, Trauma, Surgical DirectorLeadership
Elyce Frabotta
Regional Clinical Trauma And Burn DirectorLeadership
Mike Cadigan
Chief Financial OfficerLeadership
Brett Chappell
Regional Business DirectorLeadership
Steve Dibiasio
Chief Sales OfficerLeadership
Keith Covill
Executive Area Director - Western U.s.Leadership
Raz Rasmussen
Director Of Sales - MidsouthLeadership
Kyle Thompson
Regional DirectorLeadership
Travis Knight
Clinical Sales Training DirectorLeadership
Al A. Pagliarulo
Director, Strategic Enterprise Accounts - EastLeadership
Michael Walsh
Director Of Field ReimbursementLeadership
Gudmundur Magnus Hermannsson
VP Strategic ProjectsLeadership
Colleen Brennan
Director Of Post Market Clinical ResearchLeadership

109 more people are available in the full profile.

Premium access

Complete people profiles for Kerecis

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Kerecis

Kerecis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Phytoceuticals.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Wound healing products are manufactured by Phytoceuticals in Switzerland.
phytoceuticals.chAdliswil, Switzerland2015Feb 2019••••
Premium access

Complete acquisition details for Kerecis

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Kerecis

6 dated milestones of Kerecis across 16 years, from founding to its latest funding, stage changes and deals.

  1. Founded Kerecis is founded.
  2. Funding First funding round.
  3. Acquisition Acquires Phytoceuticals.
  4. Funding Latest funding round, Series D, of $30.0M.
  5. Milestone Reaches Minicorn status.
  6. Exit Acquired by Coloplast.

Web traffic of Kerecis

The website of Kerecis (kerecis.com) receives about 26.1K visits a month.

  • Monthly visits
    26.1K

    ▲ 91.6% vs previous month

Similar websites

Websites whose visitors overlap most with Kerecis. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
clinicaltrials.gov
100%
3.3M#13,034View details
woundreference.com
93%
15.7K#1,476,557View details
vivex.com
91%
7.2K#3,030,609View details
healor.com
87%
11.5K#1,978,831View details
organogenesis.com
86%
14.8K#1,257,959View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 12 similar websites and full traffic analytics for Kerecis

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 12 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Kerecis

Premium access

Complete news archive for Kerecis

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kerecis

Kerecis was founded in 2007 and raised its 1st funding round 3 years after it was founded.

Kerecis is headquartered in Isafjordur, Iceland.

Kerecis is a funded company, having raised a total of $93.11M across 14 funding rounds to date. The company's 1st funding round was a Series B of $3M, raised on Jan 2010.

Kerecis has 150 employees.

Founded in 2007 in Isafjordur, Iceland, the company operates in the medical technology sector, focusing on acellular fish-skin grafts. Omega3 technology is utilized in products for chronic wound management, hernia repair, breast reconstruction, and abdominal wall reconstruction. Advantages over human and porcine alternatives include better economics, enhanced clinical outcomes, lower disease transmission risks, and no cultural usage barriers. The domain kerecis.com supports global operations.

Kerecis offers MariGen, SurgiClose, SurgiBind, GraftGuide, and 2 more products and services.

Kerecis has made 1 acquisition, including Phytoceuticals.

Kerecis has 8 investors. Key investors include SVB, Coloplast, European Union, KIRKBI, and LSR.

The valuation of Kerecis is $620M as of Jul 2022.

Kerecis operates through Kerecis, Llc.

Yes. Kerecis was acquired by Coloplast in July 2023.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available